Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Relation Between Serum IGF-1 & BMI In Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05301569
Recruitment Status : Not yet recruiting
First Posted : March 29, 2022
Last Update Posted : March 29, 2022
Sponsor:
Information provided by (Responsible Party):
Rania Sallam Mohamed Taha, Assiut University

Brief Summary:
cross-sectional study in which participants will be recruited at dermatology & Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists & obtaining an informed consent

Condition or disease
Evaluation of Serum Level of Insulin Like Growth Factor 1

Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris
Estimated Study Start Date : May 1, 2022
Estimated Primary Completion Date : March 30, 2023
Estimated Study Completion Date : October 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne




Primary Outcome Measures :
  1. Evaluation of serum level of insulin like growth factor 1 in acne vulgaris [ Time Frame: 1 year ]
    using the Chemiluminescent Microparticle Immunoassay



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Acne vulgaris patients aged from 15 to 45 years old
Criteria

Inclusion Criteria:

  1. Patients aged from 15 to 45 years old suffering from acne vulgaris.
  2. Both sexes.

Exclusion Criteria:

  1. Insulin resistance and diabetic patients
  2. Females with polycystic ovarian syndrome
  3. Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study.
  4. Other causes of acne or acneform eruption as steroid-induced
Layout table for additonal information
Responsible Party: Rania Sallam Mohamed Taha, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT05301569    
Other Study ID Numbers: IGF-1 in AV
First Posted: March 29, 2022    Key Record Dates
Last Update Posted: March 29, 2022
Last Verified: March 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases